Skip to main content
by SciGen® Technologies S.A. All rights reserved.
15th to 17th Nov , 2013 | Helsinki, Finland
Posters by ID
Posters by Title
Phase II study with everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: activity data in pNET and non-pNET patients from the I.T.M.O. (Italian trials in medical oncology) group
Poster Presenter: Stefanos Manolakis
Give it 1/5
Give it 2/5
Give it 3/5
Give it 4/5
Give it 5/5
No votes yet
Copyright © 2015-2019,
SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.
Enter Poster ID (e.gGoNextPreviousCurrent